Edition:
United Kingdom

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

44.80USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$44.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
178,658
52-wk High
$58.80
52-wk Low
$29.90

Select another date:

Tue, Nov 14 2017

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11

* Pacira Pharmaceuticals Inc reports third quarter 2017 financial results

BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio

* Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​

BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA

* Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia

BRIEF-‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​

* ‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​ Source text: (http://bit.ly/2io69IV) Further company coverage:

BRIEF-Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals

* Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​ Source text for Eikon: (http://bit.ly/2fEM3Jn) Further company coverage:

BRIEF-Pacira Pharma says data on Exparel published in medical journal

* Pacira announces publication of phase 4 study of exparel in patients undergoing total knee replacement in the journal of arthroplasty Source text for Eikon: Further company coverage:

BRIEF-Pacira announces topline phase 3 results for Exparel

* Pacira announces topline phase 3 results for Exparel as a single-dose nerve block

Select another date: